CSBR - Champions Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.84
+0.09 (+0.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.75
Open9.60
Bid9.00 x 1200
Ask11.20 x 1800
Day's Range9.35 - 10.19
52 Week Range3.05 - 17.90
Volume78,358
Avg. Volume250,660
Market Cap109.858M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateDec 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

    HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018. The company will host a conference call to discuss the second quarter results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 41544, or by accessing the Investor tab of the company's website within 72 hours.

  • Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
    Zacks23 days ago

    Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Champions Oncology (CSBR) closed at $10.39, marking a +0.39% move from the previous day.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswirelast month

    Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

    HACKENSACK, N.J., Nov. 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Craig Hallum representative or Hayden IR at james@haydenir.com. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.

  • Champions Oncology Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Champions Oncology Sees Hammer Chart Pattern: Time to Buy?

    Champions Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

  • Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
    Zacks2 months ago

    Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?

    Is (CSBR) Outperforming Other Medical Stocks This Year?

  • Champions Oncology (CSBR) Gains As Market Dips: What You Should Know
    Zacks2 months ago

    Champions Oncology (CSBR) Gains As Market Dips: What You Should Know

    Champions Oncology (CSBR) closed at $12.21 in the latest trading session, marking a +0.58% move from the prior day.

  • Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
    Zacks2 months ago

    Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?

    Is (CSBR) Outperforming Other Medical Stocks This Year?

  • Bull Of The Day: Champions Oncology (CSBR)
    Zacks2 months ago

    Bull Of The Day: Champions Oncology (CSBR)

    Bull Of The Day: Champions Oncology (CSBR)

  • Best ETFs & Stocks From the Top Sector of Q3
    Zacks2 months ago

    Best ETFs & Stocks From the Top Sector of Q3

    Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

  • Zacks3 months ago

    Tech Breaks S&P Out of Slump

    Tech Breaks S&P Out of Slump

  • Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice
    Zacks3 months ago

    Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice

    Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Zacks3 months ago

    S&P, Dow Nearing All-Time Highs

    S&P, Dow Nearing All-Time Highs

  • PR Newswire3 months ago

    Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

    Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range ...

  • PR Newswire3 months ago

    Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

    HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 on Monday, September 17th in New York. To schedule a meeting, please contact your conference representative or James Carbonara at Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.

  • Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?
    Zacks3 months ago

    Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?

    Champions Oncology (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire4 months ago

    Champions Oncology to Announce First Quarter Financial Results on Thursday, September 13, 2018

    HACKENSACK, N.J., Aug. 28, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2018, on Thursday, September 13, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 37415, or by accessing the Investor tab of the company's website within 72 hours.

  • PR Newswire4 months ago

    Champions Oncology Granted Full Accreditation by the AAALAC

     The new facility was designed and constructed in the first half of 2017 with operations initiated in July 2017. The purpose-built facility has state-of-the-art equipment, technology, and infrastructure, including individually ventilated caging, and automated water systems. Dr. Ronnie Morris, CEO of Champions Oncology commented: "The rapidity with which our Program attained Full Accreditation by AAALAC highlights our dedication to animal welfare and providing the highest quality research data to our collaborators. AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Nearly 1,000 companies, universities, hospitals, government agencies and other research institutions in 46 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use.

  • PR Newswire5 months ago

    Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

    Expects Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions ...

  • PR Newswire5 months ago

    Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 26, 2018

    HACKENSACK, N.J., July 12, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2018, on Thursday, July 26, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 34360, or by accessing the Investor tab of the company's website within 72 hours.

  • PR Newswire6 months ago

    Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

    HACKENSACK, N.J., June 18, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials. The first trial, NSABP FB10 is a phase II study evaluating the combination of trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer (NCT02236000) and is currently enrolling patients.

  • PR Newswire7 months ago

    Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th

    HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices located at 599 Lexington Avenue. The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

  • PR Newswire8 months ago

    Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research

    HACKENSACK, N.J., May 1, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research. Ronnie Morris, CEO of Champions Oncology commented, "The appointment of Dr. Wesa demonstrates our long-term commitment to help pharmaceutical companies make better decisions as they develop immunotherapeutics. Immuno-oncology represents a fast growing part of the oncology drug pipeline.

  • PR Newswire8 months ago

    Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

    HACKENSACK, N.J., April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 9:30am. The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th.

  • ACCESSWIRE9 months ago

    Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes

    Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...